Medical Information

Triumeq is a three in one compound single tablet formulation used for the treatment of HIV-1 infection, containing three active ingredients: cetuximab, abacavir, and lamivudine. This drug works by inhibiting key enzymes involved in virus replication and is suitable for both adult and pediatric patients. Strict adherence to dosage and medication guidelines is necessary to ensure efficacy and safety.

1. Composition and mechanism of action

Triumeq is composed of Doitavir (integrase inhibitor), Abacavir, and Lamivudine (nucleoside reverse transcriptase inhibitor). Duotelamivir blocks the integration of viral DNA into host cells, while the latter two inhibit replication by terminating viral DNA strand synthesis. Compound design simplifies medication plans and improves compliance.

2 Indications, usage and dosage

Suitable for the treatment of HIV-1 infection in adults and adolescents weighing ≥ 40kg. The standard dose is one tablet taken orally once a day, which can be taken with or without food. Pediatric patients should adjust their dosage according to their weight and undergo HLA-B * 5701 gene screening before use to avoid the risk of abacavir allergy.

3 Medication precautions

(1) Allergic reactions: Abacavir should not be used in HLA-B * 5701 positive patients, as it may cause fatal hypersensitivity reactions; (2) Liver function monitoring: patients with hepatitis B complicated with infection should be alert to hepatitis recurrence after drug withdrawal; (3) Drug interactions: Drugs containing multivalent cations should be taken at 4-hour intervals to avoid reducing the absorption of Doitavir.

4 Adverse Reaction Management

Common adverse reactions include headache, insomnia, nausea, etc; Serious adverse reactions may involve allergies, lactic acidosis, or hepatotoxicity. If symptoms such as rash, fatigue, and abdominal pain occur, seek medical attention immediately. Long term use requires regular monitoring of liver function, blood lipids, and immune reconstitution.

Medication for 5 special populations

(1) Pregnancy period: It is necessary to weigh the pros and cons, as Doxetine may increase the risk of neural tube defects; (2) Breastfeeding period: HIV infected individuals should avoid breastfeeding; (3) Liver and kidney damage: Mild to moderate dose adjustment is not necessary, severe cases require careful evaluation; (4) Elderly patients: may need to strengthen monitoring of adverse reactions.